Show simple item record

dc.contributor.authorKirenga, Bruce
dc.contributor.authorByakika-Kibwika, Pauline
dc.contributor.authorMuttamba, Winters
dc.contributor.authorKayongo, Alex
dc.contributor.authorNamakula, Olive Loryndah,
dc.contributor.authorMugenyi, Levicatus
dc.contributor.authorKiwanuka, Noah
dc.contributor.authorLusiba, John
dc.contributor.authorAtukunda, Angella
dc.contributor.authorMugume, Raymond
dc.contributor.authorSsali, Francis
dc.contributor.authorDdungu, Henry
dc.contributor.authorKatagira, Winceslaus
dc.contributor.authorSekibira, Rogers
dc.contributor.authorKityo, Cissy
dc.contributor.authorKyeyune, Dorothy
dc.contributor.authorAcana, Susan
dc.contributor.authorAanyu-Tukamuhebwa, Hellen
dc.contributor.authorKabweru, Wilberforce
dc.contributor.authorNakwagala, Fred
dc.contributor.authorSentalo Bagaya, Bernard
dc.contributor.authorKimuli, Ivan
dc.contributor.authorNantanda, Rebecca
dc.contributor.authorBuregyeya, Esther
dc.contributor.authorByarugaba, Baterana
dc.contributor.authorOlaro, Charles
dc.contributor.authorMwebesa, Henry
dc.contributor.authorLutaakome Joloba, Moses
dc.contributor.authorSiddharthan, Trishul
dc.contributor.authorBazeyo, William
dc.date.accessioned2022-01-12T10:31:40Z
dc.date.available2022-01-12T10:31:40Z
dc.date.issued2021
dc.identifier.citationKirenga B, Byakika-Kibwika P, Muttamba W, et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ Open Resp Res 2021;8:e001017. doi:10.1136/ bmjresp-2021-001017en_US
dc.identifier.other10.1136/ bmjresp-2021-001017
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1215
dc.description.abstractConvalescent plasma (CCP) has been studied as a potential therapy for COVID-19, but data on its efficacy in Africa are limited. Objective In this trial we set out to determine the efficacy of CCP for treatment of COVID-19 in Uganda. Measurements Patients with a positive SARS-CoV- 2 reverse transcriptase (RT)-PCR test irrespective of disease severity were hospitalized and randomized to receive either COVID-19 CCP plus standard of care (SOC) or SOC alone. The primary outcome was time to viral clearance, defined as having two consecutive RT-PCR- negative tests by day 28. Secondary outcomes included time to symptom resolution, clinical status on the modified WHO Ordinal Clinical Scale (≥1-point increase), progression to severe/ critical condition (defined as oxygen saturation <93% or needing oxygen), mortality and safety.en_US
dc.language.isoenen_US
dc.publisherBMJ Open Resp Resen_US
dc.subjectConvalescent plasmaen_US
dc.subjectTreatmenten_US
dc.subjectCOVID-19en_US
dc.subjectUgandaen_US
dc.titleEfficacy of convalescent plasma for treatment of COVID-19 in Ugandaen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record